ENGN vs. SDGR, XNCR, ARDX, NRIX, KNSA, RCUS, OCUL, MRVI, ARVN, and PRAX
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Schrödinger (SDGR), Xencor (XNCR), Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Arvinas (ARVN), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
enGene vs.
enGene (NASDAQ:ENGN) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Schrödinger received 37 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 56.99% of users gave Schrödinger an outperform vote.
In the previous week, enGene had 2 more articles in the media than Schrödinger. MarketBeat recorded 6 mentions for enGene and 4 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.40 beat enGene's score of -0.47 indicating that Schrödinger is being referred to more favorably in the news media.
64.2% of enGene shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 8.6% of Schrödinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
enGene presently has a consensus target price of $29.78, indicating a potential upside of 317.06%. Schrödinger has a consensus target price of $32.90, indicating a potential upside of 73.16%. Given enGene's stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than Schrödinger.
Schrödinger has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.
enGene has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
enGene has a net margin of 0.00% compared to Schrödinger's net margin of -91.84%. enGene's return on equity of -16.69% beat Schrödinger's return on equity.
Summary
enGene beats Schrödinger on 10 of the 17 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:ENGN) was last updated on 1/20/2025 by MarketBeat.com Staff
Free ENGN Stock Alerts